This course will run from 23 April – 24 April 2020 in Pavia, Italy
THURSDAY 23 APRIL
|09:00||Regulatory affairs and GMP production
|Regulatory affairs – update|
|GMP production of ATMPs for clinical use||G Astori, Vicenza|
|GMP production of biologicals for clinical use||A Peterbauer, Linz|
|A model of a publicly funded institution supporting the development of ATMPs||N Cuende, Seville|
|11:30||Cell therapy: where do we stand?|
|What can be truly regenerated?|
|From cells to cell products|
|14:00||Secretome and extracelluar vesicles|
|MSC conditioned media for tissue repair||M Gnecchi, Pavia|
|Biological properties of extracellular vesicles and their physiological functions||B Giebel, Essen|
|Extracellular vesicles for tissue repair – Systems biology approaches to investigating the therapeutic potential of extracellular vesicles|
|Stressed PBMCS secretome – content/function and therapeutic indications||H J Ankersmit, Vienna|
|14:00||Young Investigator Session|
|How to build a successful career in cell therapy||M Dominici, Modena|
FRIDAY 24 APRIL
|08:30||ATMPs versus biologicals for tissue repair|
|Safety testing of biologics and advanced therapies|
|How Holoclar became the first stem cell product approved in Europe||G Pellegrini, Modena|
|MSC secretome – relevance in neurological indications||A Salgado, Braga|
|Successful translation of cell secretome in diabetic foot ulcer clinical trial||G Gouya, Vienna|
|11:00||Clinical and translation studies testing cell-based therapies for cardiovascular diseases|
|Cell therapy trials for heart regeneration – lessons learned and future directions||P Menasche, Paris|
|BMC and the BAMI trial||S Janssens, Leuven|
|Discovery of secretome-derived molecules for heart repair||K Wollert, Hanover|
|How the CRISP technology will change medicine||B Levine, Philadelphia|
|iPSC in 2020||J S Hulot, Paris|
|miRNA levels in a model of osteoporosis and therapy|
|microRNA and heart repair: what’s new?|
|16:00||Tissue engineering: where do we stand in 2020?|
|Tissue engineering of the future||I Martin, Basel|
|Decellularization for tissue regeneration|
|Engineered valves||J Kluin, Amsterdam|
|Tissue and organ 3D bioprinting|
|17:30||Winners of best abstracts and best posters and closing remarks|
23 April- 24 April 2020 (2 day course)
Almo Collegio Borromeo
M Gnecchi, Pavia; HJ Ankersmit, Vienna
The 2 day programme will include keynote presentations, a young investigator session and poster presentation.
Delegates: €200 inclusive of VAT
Industry: €275 inclusive of VAT
Students: €50 inclusive of VAT
Fee includes lunch and refreshments on 23 and 24 April.
Cardio-thoracic surgeons and Cardiologists interested in translational science, professionals involved with regulatory affairs in applied research and the translation of ATMP and secretome based regenerative products to the bedside. Basic Scientists, Biologists, Biotechnologists, Residents and Fellows of all surgical and clinical specialities, particularly the youngest.
Participants will learn the latest advancements in the field of cell and molecular therapy for tissue repair. The use of specific cell populations (ATMPs) and cell derived molecules (such as proteins and microvescicles) for the treatment of different diseases will be discussed. Also, an update on cell and tissue engineering developments will be presented.
A further objective of this symposium is the description of the complex interplay between regulatory affairs and basic/translational science in order to transfer scientific research to the patients.
Click here to view the call for abstracts.